Protocol Ledger

NCT05881408 · Phase III · ACTIVE NOT RECRUITING

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Interventional Phase III clinical trial protocol NCT05881408 sponsored by Sarepta Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-31 Enrollment: 148 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05881408
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)148 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05881408
Protocol FieldVerified Registry Value
NCT IdentifierNCT05881408
Consolidated Lead SponsorSarepta Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment148 participants (ESTIMATED)
Registered Start Date2023-05-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI